Intra-Cellular Therapies Inc. (NASDAQ:ITCI) Director Christopher D. Alafi acquired 34,000 shares of Intra-Cellular Therapies stock in a transaction on Monday, November 14th. The shares were bought at an average cost of $14.50 per share, with a total value of $493,000.00. Following the completion of the purchase, the director now owns 730,529 shares in the company, valued at $10,592,670.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) traded up 2.06% on Friday, hitting $13.86. The company had a trading volume of 257,057 shares. The company has a 50 day moving average of $13.49 and a 200-day moving average of $32.74. Intra-Cellular Therapies Inc. has a 12-month low of $10.80 and a 12-month high of $59.96. The company’s market cap is $599.69 million.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.84) by $0.14. The company earned $4.36 million during the quarter, compared to the consensus estimate of $0.04 million. Intra-Cellular Therapies’s quarterly revenue was up NaN% on a year-over-year basis. During the same period in the prior year, the company posted ($0.91) EPS. On average, analysts forecast that Intra-Cellular Therapies Inc. will post ($2.84) earnings per share for the current year.

Several analysts have commented on ITCI shares. Cowen and Company reaffirmed a “buy” rating and set a $75.00 price objective on shares of Intra-Cellular Therapies in a research note on Friday, August 5th. Leerink Swann reiterated a “buy” rating and set a $95.00 target price on shares of Intra-Cellular Therapies in a research report on Thursday, August 11th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $57.00 target price on shares of Intra-Cellular Therapies in a research report on Tuesday, September 13th. SunTrust Banks Inc. cut Intra-Cellular Therapies from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $60.00 to $15.00 in a research report on Thursday, September 29th. Finally, Royal Bank Of Canada dropped their target price on Intra-Cellular Therapies from $74.00 to $49.00 and set an “outperform” rating on the stock in a research report on Thursday, September 29th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company’s stock. Intra-Cellular Therapies has a consensus rating of “Hold” and a consensus price target of $42.00.

Hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada increased its stake in shares of Intra-Cellular Therapies by 23.1% in the second quarter. Royal Bank of Canada now owns 2,684 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 504 shares during the period. Bank of Montreal Can purchased a new stake in shares of Intra-Cellular Therapies during the second quarter valued at about $155,000. Mycio Wealth Partners LLC boosted its stake in shares of Intra-Cellular Therapies by 14.3% in the second quarter. Mycio Wealth Partners LLC now owns 4,398 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 550 shares in the last quarter. Teacher Retirement System of Texas boosted its stake in shares of Intra-Cellular Therapies by 13.7% in the second quarter. Teacher Retirement System of Texas now owns 4,532 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 546 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Intra-Cellular Therapies by 29.3% in the second quarter. Legal & General Group Plc now owns 5,282 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 1,197 shares in the last quarter. 65.39% of the stock is currently owned by institutional investors.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

5 Day Chart for NASDAQ:ITCI

Receive News & Stock Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related stocks with our FREE daily email newsletter.